HK inno.N, a Korean pharmaceutical company, announced its strategic entry into the rapidly growing global obesity treatment market through a partnership with Sciwind Biosciences, a Chinese biotech firm.
HK inno.N CEO Kwak Dal-won (left) and Sciwind CEO Hai Pan hold up the license agreement at Sciwind R&D Center in Beijing, China, on Tuesday. (credit: HK inno.N)
This collaboration is centered around the development and commercialization of Sciwind Biosciences’ glucagon-like…
Read More…
Source: https://www.koreabiomed.com/news/articleViewAmp.html?idxno=23952